ADARx Pharmaceuticals — Third Quarter 2026 Earnings Summary

ADARx Pharmaceuticals completed its initial public offering and a concurrent private placement, generating approximately $602.5 million in aggregate gross proceeds. The company advanced three Phase 2 clinical trials for its lead candidate agazisiran to treat complement-mediated diseases and received Fast Track designation from the FDA for onvuzosiran in hereditary angioedema. For the third quarter ended September 30, 2026, the company reported collaboration revenue of $2.2 million, research and development expenses of $26.7 million, and a net loss of $28.1 million. As of the end of the quarter, ADARx held $901.0 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into 2030.